TL;DR
This work proposes a biology-driven clustering in a large cohort if subjects with iPD if subjects belonging to the ''Mixed Pathology'' subtype included subjects whose biomarker signature did not indicate predominant alterations in any of the explored pathways.
These findings support the use of pathway-specific biomarkers for improving PD diagnostics and monitoring disease progression and support the use of pathway-specific biomarkers for improving PD diagnostics and monitoring disease progression.
These findings, replicated in four diverse and independent datasets, support imaging-based subtyping as a scalable and clinically translatable approach for capturing heterogeneity in AD pathophysiology and associated cognitive trajectories.
Evidence from MRI-based subtyping studies that used structural, diffusion, functional, or multimodal MRI features as primary inputs for unsupervised or hybrid ML approaches to derive PD subtypes is synthesizes and outlines key methodological challenges and future translational needs.
BACKGROUND Parkinson's disease (PD) is frequently accompanied by neuropsychiatric symptoms (NPS), including cognitive impairment, which often emerge early and co-occur. Their long-term evolution remains incompletely characterized, particularly in biomarker-positive cohorts. OBJECTIVE The aim was to examine the evolut...
Cell-type enrichment analysis indicating a broad cellular origin of the circulating proteome, with contributions from nervous system cells, vascular cells, immune cells, and muscle cells, highlights the potential of plasma proteomics for clinically meaningful patient stratification in ALS.
Parkinson’s disease (PD) is a heterogeneous disorder with distinct phenotypes that may emerge years before motor diagnosis. We investigated the proposed “body-first” and “brain-first” PD phenotypes across prodromal and clinical stages using longitudinal clinical, imaging, and genetic data from 2,030 participants in the...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
